TG Therapeutics (FRA:NKB2) Growth Rank: 9 (As of Sep. 09, 2026) — 50% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NKB2 TG Therapeutics Inc FRA:NKB2
60 GF Score
Price €47.40
GF Value €52.12
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is TG Therapeutics Growth Rank?

TG Therapeutics FRA:NKB2 -0.42% 60 Growth Rank is 9 as of Sep. 09, 2026, which is 50% above its 10-year median of 6.00. GuruFocus rates FRA:NKB2 with a GF Score™ of 60/100 and a GF Value™ of €52.12 (Fairly Valued). The stock has 6 warning signs investors should review.

TG Therapeutics has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

TG Therapeutics Growth Rank Related Terms

FRA:NKB2 vs IMVT, SYRE, IBRX: Growth Rank Comparison

For the Biotechnology subindustry, TG Therapeutics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TG Therapeutics Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Growth Rank distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Growth Rank falls into.


FRA:NKB2
60GF Score
TG Therapeutics Inc FRA:NKB2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
TG Therapeutics (FRA:NKB2) has a Growth Rank of 9 as of Sep. 09, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on TG Therapeutics and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, TG Therapeutics' Growth Rank has ranged from 1.00 to 10.00.
Is TG Therapeutics' Growth Rank too high?
TG Therapeutics' current Growth Rank of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, TG Therapeutics has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Growth Rank compare to IMVT and SYRE?
TG Therapeutics' Growth Rank of 9 can be compared against companies in the Biotechnology industry. Historically, TG Therapeutics' own Growth Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Growth Rank is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €52.12, compared to a current price of €47.40 — trading 9.1% below its estimated fair value. The current Growth Rank is 9, which is 50% above median its 10-year median of 6.00. TG Therapeutics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Growth Rank is 9 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €47.40 is trading 9.1% below its estimated GF Value™ of €52.12. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for FRA:NKB2:

  • Growth Rank: 9 (50% above median its 10-year median of 6.00)
  • GF Value™: €52.12 vs. price of €47.40 (9.1% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
60GF Score

Get the complete analysis for FRA:NKB2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€47.40
Price
€52.12
GF Value